AG Nelson (Chemokines, stromal cells, cancer)
Professor Peter J. Nelson BS PhD
Medizinische Klinik und Poliklinik IV
Professor of Immunology and Molecular Medicine
Nephrologie Zentrum, AG Klinische Biochemie
Peter J. Nelson is a Professor of Immunology and Molecular Medicine at the University of Munich Clinics. His research broadly addresses issues related to chronic inflammation, the application of engineered adult stem cells as a therapeutic modality, gene promoter engineering, bioinformatics, chemokine, and protease biology. The pathophysiologic mechanisms underlying the induction and propagation of chronic fibrosis and tissue damage represent important aspects of his work.
Qualifications
- BS (Biochemistry) University of Minnesota 1984
- PhD (Biochemistry and Molecular Immunology) University of Minnesota 1989
- Habilitation (Immunology) Ludwig-Maximilians- University Munich 2001
Biography
Peter Nelson completed his BS in Biochemistry in 1984, and then pursued a PhD in Biochemistry and Molecular Immunology from the University of Minnesota. He completed his thesis in the laboratory of Prof. Fritz H. Bach in 1989 and focused on molecular characterization of the development of T-cell effector function.
Subsequently Peter took a postdoctoral position in the laboratory of Prof. Dolores Schendel at the Institute of Immunology, Ludwig-Maximilians-University Munich where he studied major histocompatibility (MHC) biology as it applied to the characterization of antigenic mimicry. He then took a postdoctoral scholar position at Stanford University School of Medicine where he obtained fellowships from the American Heart Association and the National Institutes of Health in the US. In the laboratory of Prof. Alan M. Krensky, his work centered on the biology of chemotactic cytokines (chemokines) and their role in acute and chronic inflammatory disease. Work also included protein structure-function experiments as well as the identification of molecular mechanisms underlying signal and tissue-specific transcriptional regulation.
After four years at Stanford, Peter was recruited to Munich and the LMU by Prof. Detlef Schlöndorff where he established himself as a group leader, completing his habilitation in Immunology in 2001 and progressed to an apl Professorship in 2010.
Teaching
- MECUM
- Dr. med projects
- Dr. hum biol, Dr rer nat and PhD projects
Graduate and Postgraduate supervision
- 30+ previous MS, PhD and MD students
- 3 current Dr. hum biol and Dr. rer nat students and 4 medical students funded by the DFG and FoFöLe.
Research
- The application of engineered mesenchymal stem cells as a therapeutic modality for the treatment of cancer, chemokine and protease biology
- The pathophysiologic mechanisms underlying the induction and propagation of chronic fibrosis
- Model systems for understanding basic biologic mechanisms driving chronic fibrotic disease.
- Divers mechanisms of thyroid hormone biology in the context of mesenchymal stem cell-mediated tumor therapy (in collaboration with Prof. C. Spitzweg).
- Murine models of tumorigenesis
Other activities
Fachimmunologe
Issuing authority Deutsche Gesellschaft für Immunologie (DGfI)
Publications
Recent publications
Articles
Tutter M, Schug C, Schmohl KA, Urnauer S, Kitzberger C, Schwenk N, Petrini M, Zach C, Ziegler S, Bartenstein P, Weber WA, Multhoff G, Wagner E, Lindner LH, Nelson PJ, Spitzweg C. Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy. Mol Ther. 2021 Feb 3;29(2):788-803. doi: 10.1016/j.ymthe.2020.10.009.
Schmohl KA, Han Y, Tutter M, Schwenk N, Sarker RSJ, Steiger K, Ziegler SI, Bartenstein P, Nelson PJ, Spitzweg C. Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation. Endocr Relat Cancer. 2020 Dec;27(12):685-697. doi: 10.1530/ERC-20-0353.
Wang Z, Qin J, Zhao J, Li J, Li D, Popp M, Popp F, Alakus H, Kong B, Dong Q, Nelson PJ, Zhao Y, Bruns CJ. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics. 2020 Jun 1;10(16):7178-7192. doi: 10.7150/thno.43093. eCollection 2020.
Zheng Y, Wu C, Yang J, Zhao Y, Jia H, Xue M, Xu D, Yang F, Fu D, Wang C, Hu B, Zhang Z, Li T, Yan S, Wang X, Nelson PJ, Bruns C, Qin L, Dong Q. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 2020 May 13;5(1):53. doi: 10.1038/s41392-020-0146-6.
Tutter M, Schug C, Schmohl KA, Urnauer S, Schwenk N, Petrini M, Lokerse WJM, Zach C, Ziegler S, Bartenstein P, Weber WA, Wagner E, Lindner LH, Nelson PJ, Spitzweg C. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells. Theranostics. 2020 Mar 15;10(10):4490-4506. doi: 10.7150/thno.41489. eCollection 2020.
Brett E, Sauter M, Timmins É, Azimzadeh O, Rosemann M, Merl-Pham J, Hauck SM, Nelson PJ, Becker KF, Schunn I, Lowery A, Kerin MJ, Atkinson M, Krüger A, Machens HG, Duscher D.J Oncogenic Linear Collagen VI of Invasive Breast Cancer Is Induced by CCL5. Clin Med. 2020 Apr 2;9(4):991. doi: 10.3390/jcm9040991.
Schmohl KA, Mueller AM, Dohmann M, Spellerberg R, Urnauer S, Schwenk N, Ziegler SI, Bartenstein P, Nelson PJ, Spitzweg C. Integrin αvβ3-Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. Thyroid. 2019 Dec;29(12):1843-1857. doi: 10.1089/thy.2019.0413.
Sun HR, Wang S, Yan SC, Zhang Y, Nelson PJ, Jia HL, Qin LX, Dong QZ Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Front Oncol. 2019 Oct 24;9:1104. doi: 10.3389/fonc.2019.01104..
Schmohl KA, Müller AM, Nelson PJ, Spitzweg C Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment..Exp Clin Endocrinol Diabetes. 2020 Jun;128(6-07):462-468. doi: 10.1055/a-1022-9874.
Zhao Y, Li J, Li D, Wang Z, Zhao J, Wu X, Sun Q, Lin PP, Plum P, Damanakis A, Gebauer F, Zhou M, Zhang Z, Schlösser H, Jauch KW, Nelson PJ, Bruns CJ. Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers. Semin Cancer Biol. 2020 Feb;60:334-343. doi: 10.1016/j.semcancer.2019.08.026.
Schug C, Kitzberger C, Sievert W, Spellerberg R, Tutter M, Schmohl KA, Eberlein B, Biedermann T, Steiger K, Zach C, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene 131I Therapy. C.Clin Cancer Res. 2019 Oct 1;25(19):5997-6008. doi: 10.1158/1078-0432.CCR-18-4092.
Schmohl KA, Nelson PJ, Spitzweg C. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer. 2019 Jun 1;26(6):R287-R304. doi: 10.1530/ERC-19-0058.
Zhang XF, Wang J, Jia HL, Zhu WW, Lu L, Ye QH, Nelson PJ, Qin Y, Gao DM, Zhou HJ, Qin LX. Core fucosylated glycan-dependent inhibitory effect of QSOX1-S on invasion and metastasis of hepatocellular carcinoma. Cell Death Discov. 2019 Apr 3;5:84. doi: 10.1038/s41420-019-0164-8. eCollection 2019.
von Einem JC, Guenther C, Volk HD, Grütz G, Hirsch D, Salat C, Stoetzer O, Nelson PJ, Michl M, Modest DP, Holch JW, Angele M, Bruns C, Niess H, Heinemann V. Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial. Int J Cancer. 2019 Sep 15;145(6):1538-1546. doi: 10.1002/ijc.32230.
Schug C, Gupta A, Urnauer S, Steiger K, Cheung PF, Neander C, Savvatakis K, Schmohl KA, Trajkovic-Arsic M, Schwenk N, Schwaiger M, Nelson PJ, Siveke JT, Spitzweg C. A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. Mol Cancer Res. 2019 Jan;17(1):310-320. doi: 10.1158/1541-7786.MCR-18-0185.
Schug C, Urnauer S, Jaeckel C, Schmohl KA, Tutter M, Steiger K, Schwenk N, Schwaiger M, Wagner E, Nelson PJ, Spitzweg C. TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer. Endocr Relat Cancer. 2019 Jan 1;26(1):89-101. doi: 10.1530/ERC-18-0173.
Schwarzenböck C , Nelson PJ , Huss R , Rieger B . Synthesis of next generation dual-responsive cross-linked nanoparticles and their application to anti-cancer drug delivery.Nanoscale. 2018 Aug 30;10(34):16062-16068. doi: 10.1039/c8nr04760j.
Zhao Y, Dong Q, Li J, Zhang K, Qin J, Zhao J, Sun Q, Wang Z, Wartmann T, Jauch KW, Nelson PJ, Qin L, Bruns C. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. Semin Cancer Biol. 2018 Dec;53:139-155. doi: 10.1016/j.semcancer.2018.08.002.
Schwarzenböck C, Vagin SI, Heinz WR, Nelson PJ, Rieger B. Studies on the Biocompatibility of Poly(diethyl vinyl-phosphonate) with a New Fluorescent Marker. Macromol Rapid Commun. 2018 Aug;39(15):e1800259. doi: 10.1002/marc.201800259.
Schug C, Sievert W, Urnauer S, Müller AM, Schmohl KA, Wechselberger A, Schwenk N, Lauber K, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg C. External Beam Radiation Therapy Enhances Mesenchymal Stem Cell-Mediated Sodium-Iodide Symporter Gene Delivery. Hum Gene Ther. 2018 Nov;29(11):1287-1300. doi: 10.1089/hum.2018.025.
Schwarzenböck C, Schaffer A, Nößner E, Nelson PJ, Huss R, Rieger B. Fluorescent Polyvinylphosphonate Bioconjugates for Selective Cellular Delivery. Chemistry. 2018 Feb 21;24(11):2584-2587. doi: 10.1002/chem.201706034.
Seeger H, Lindenmeyer MT, Cohen CD, Jaeckel C, Nelson PJ, Chen J, Edenhofer I, Kozakowski N, Regele H, Boehmig G, Brandt S, Wuethrich RP, Heikenwalder M, Fehr T, Segerer S. Lymphotoxin expression in human and murine renal allografts. PLoS One. 2018 Jan 4;13(1):e0189396. doi: 10.1371/journal.pone.0189396.